Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to register

SAGETRACK
Journal of the Society for Gynecologic Investigation
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Schneider, C. C.
Right arrow Articles by Gerçel-Taylor, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schneider, C. C.
Right arrow Articles by Gibb, R. K.
Right arrow Articles by Taylor, D. D.
Right arrow Articles by Wan, T.
Right arrow Articles by Gerçel-Taylor, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Inhibition of Endometrial Cancer Cell Lines by Mifepristone (RU 486)

Catherine C. Schneider, MD

Randall K. Gibb, MD

Douglas D. Taylor, PhD

Tina Wan, MS

Department of Obstetrics and Gynecology, University of Louisville School of Medicine, Louisville, Kentucky

Çiçek Gerçel-Taylor, PhD

Department of Obstetrics and Gynecology, University of Louisville School of Medicine, Louisville, Kentucky; cgtaylor{at}juno.com

Objective: To determine the role of mifepristone (RU 486) in the growth of endometrial cancer cell lines, and the mechanism associated with this regulation.

Methods: Three endometrial cancer cell lines (Hec-1A, KLE, and RL95-2) were used in this study. Growth inhibition was demonstrated by sulforhodamine B cytotoxicity assay. Mode of inhibition by RU 486 was studied by induction of DNA fragmentation. The effect of RU 486 on steady-state accumulation of the progesterone and glucocorticoid receptors (PRs and GRs, respectively) and apoptosis-associated gene products was studied by Western blotting.

Results: We demonstrated a dose-dependent inhibition of growth in all of the three endomentrial cancer cell lines. Following treatment with 5.0 µg/mL of RU 486, there was 39.3%, 66.3%, and 75.5% inhibition of KLE, Hec-1A, and RL95-2 cells, respectively. Decreased expression of GR in RL95-2 (0.1-10 µg/mL) and in KLE cells (10 µg-mL) was observed. A marked decrease of PR was seen with RL95-2 cells at 10 µg/mL, there was no change in the KLE cells, and a dose-dependent decrease was seen with Hec-1A cells. Various levels of apoptosis were demonstrated by DNA fragmentation in all three cell lines. Of the genes associated with apoptosis, dose-dependent reduction of bax expression was demonstrated in KLE cells, while induction of WAF-1 was seen in Hec-1A and RL95-2 cells, and reduction of bcl-2 was demonstrated in RL95-2 cells.

Conclusion: Clinically achievable doses of RU 486 inhibit endometrial cancer cell lines. The mechanism of inhibition involves apoptosis, and regulation of bax, bcl-2, and WAF-1 is demonstrated. Therapeutic application of these findings remains to be determined.

Key Words: RU 486 • endometrial cancer • apoptosis

Journal of the Society for Gynecologic Investigation, Vol. 5, No. 6, 334-338 (1998)
DOI: 10.1177/107155769800500611
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?